Ioannidis John P A
Department of Medicine, Stanford University, Stanford, California.
Department of Epidemiology and Population Health, Stanford University, Stanford, California.
JAMA Health Forum. 2025 Sep 5;6(9):e253045. doi: 10.1001/jamahealthforum.2025.3045.
It is important to monitor changes in the biomedical literature and its funding. China has surpassed the US in publications and, in some analyses, in some impact indicators.
To evaluate changes over time in the profiles of the most highly cited biomedical publications.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study assessed 100 top-cited biomedical articles (based on Scopus) published in each of 3 time periods (2003-2004, 2013-2014, and 2023-2024) for corresponding authors, types of publications represented, and funding sources, with an emphasis on funding from the US National Institutes of Health (NIH), which has been traditionally considered the major funder of biomedical research.
The main outcomes of interest are descriptive and include provenance (country of corresponding author), type of publication, type of funding, overall NIH funding, and NIH funding as the sole funding source.
Among 100 top-cited biomedical publications, corresponding authors from the US decreased over time (59 of 100 articles in 2003-2004, 58 of 100 in 2013-2014, 45 of 100 in 2023-2024). Corresponding authors from China represented 0 top-cited publications in 2003-2004, 1 in 2013-2014, and 4 in 2023-2024. There was an increase in consensus articles (10 in 2003-2004 vs 24 in 2023-2024) and in reference statistics articles (1 in 2003-2004, 10 in 2013-2014, and 11 in 2023-2024). Reviews remained common among top-cited articles, but almost always were nonsystematic. NIH funding was listed in 45 publications in 2003-2004, 50 in 2013-2014, and 23 in 2023-2024. All other countries combined surpassed US public funding in 2023-2024. Funding by NIH in combination with other funders increased from 13 articles in 2003-2204 to 22 and 21, respectively, in 2013-2014 and 2023-2024, but funding by NIH alone decreased in the last decade (32 of 100 in 2002-2003, 28 of 100 in 2013-2014, and 2 of 100 in 2023-2024). More commonly listed funding from nonprofit organizations, societies, and institutions complemented the NIH funding decline. The first authors of 7 of 45 and the corresponding authors of 14 of 45 top-cited US-based articles of 2023-2024 were listed as leaders of active NIH grants in RePORTER as of February 2025. Citation gaming became more obvious in 2023-2024 with the advent of some atypical highly cited papers and a larger share of nonsystematic reviews and consensus documents.
Results of this study suggest that, overall, the US remains a world leader regarding the most highly cited biomedical research and NIH funding retains a substantial presence among top-cited articles. However, NIH influence had decreased overall, and top-cited articles funded exclusively by NIH have almost disappeared. Strengthening public funding is essential to secure research that serves the common good.
监测生物医学文献及其资金投入的变化十分重要。在出版物数量以及某些分析中的一些影响力指标方面,中国已超过美国。
评估被引用次数最多的生物医学出版物的概况随时间的变化。
设计、背景和参与者:这项横断面研究评估了3个时间段(2003 - 2004年、2013 - 2014年和2023 - 2024年)中每年被引用次数最多的100篇生物医学文章(基于Scopus)的通讯作者、所代表的出版物类型和资金来源,重点关注美国国立卫生研究院(NIH)的资金投入,传统上NIH一直被视为生物医学研究的主要资助者。
感兴趣的主要结果是描述性的,包括出处(通讯作者所在国家)、出版物类型、资金类型、NIH的总体资金投入以及NIH作为唯一资金来源的情况。
在100篇被引用次数最多的生物医学出版物中,来自美国的通讯作者数量随时间减少(2003 - 2004年的100篇文章中有59篇,2013 - 2014年的100篇中有58篇,2023 - 2024年的100篇中有45篇)。来自中国的通讯作者在2003 - 2004年没有被引用次数最多的出版物,2013 - 2014年有1篇,2023 - 2024年有4篇。共识文章有所增加(2003 - 2004年为10篇,2023 - 2024年为24篇),参考文献统计文章也有所增加(2003 - 2004年为1篇,2013 - 2014年为10篇,202